OptiNose, Inc. (OPTN)
| Market Cap | 190.03M |
| Revenue (ttm) | 74.02M |
| Net Income (ttm) | -30.76M |
| Shares Out | 144.84M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,103 |
| Open | 1.290 |
| Previous Close | 1.260 |
| Day's Range | 1.265 - 1.330 |
| 52-Week Range | 0.800 - 2.100 |
| Beta | -0.10 |
| Analysts | Strong Buy |
| Price Target | 3.67 (+176.98%) |
| Earnings Date | May 14, 2024 |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a l... [Read more]
Full Company ProfileFinancial Performance
In 2023, OptiNose's revenue was $70.99 million, a decrease of -6.93% compared to the previous year's $76.28 million. Losses were -$35.48 million, -52.58% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OPTN stock is "Strong Buy." The 12-month stock price forecast is $3.67, which is an increase of 176.98% from the latest price.
News
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expe...
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReO...
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance
Optinose to Present at the 2023 Cantor Global Healthcare Conference
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha...
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa.
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...
Optinose to Present at the Jefferies Healthcare Conference
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time
Optinose Announces CEO Transition and Business Update
Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors
Optinose Appoints Paul Spence as Chief Commercial Officer
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...
Optinose Announces Departure of Acting Chief Financial Officer
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis